Clinical Trial Update: A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 study results are reported for ZD6474 (vandetanib, ZACTIMA) as monotherapy in hereditary medullary thyroid carcinoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Zactima (vandetanib) (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-08-31